Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus.
Steven B HeymsfieldAnnaswamy RajiSilvina GalloJie LiuAnnpey PongHakima HannachiSteven G TerraPublished in: Obesity (Silver Spring, Md.) (2020)
Meaningful reductions in HbA1c, fasting plasma glucose, BW, and SBP were observed with ertugliflozin in patients with overweight and obesity with type 2 diabetes mellitus. Ertugliflozin improved HbA1c and SBP and reduced BW across BMI subgroups. Ertugliflozin was generally well tolerated.